UBS lowered the firm’s price target on DexCom to $95 from $163 and keeps a Buy rating on the shares. The firm believes DexCom’s Q2 performance was based on execution slip-ups that can be rectified and that the long-term thesis is intact as the shift to standard of care is well underway, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM: